<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2026-3274</article-id><article-id custom-type="edn" pub-id-type="custom">QAUQIP</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3274</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Use of an individual NT-proBNP value calculator in the diagnosis of heart failure with preserved ejection fraction</article-title><trans-title-group xml:lang="ru"><trans-title>Использование калькулятора индивидуальных значений NT-proBNP для диагностики хронической сердечной недостаточности с сохраненной фракцией выброса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1612-7631</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тачилович</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Tachilovich</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тачилович Илья Олегович </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Ilya O. Tachilovich </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">ilya.tach@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0555-9404</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курносова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurnosova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курносова Анна Алексеевна </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Anna A. Kurnosova </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">a1nna4ku2@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0160-6015</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудрявцева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudrjavtseva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кудрявцева Анна Александровна  </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Anna A. Kudrjavtseva</p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">ankudr@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6753-1365</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скрипка</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Skripka</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скрипка Алена Игоревна </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Alena I. Skripka </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">alenskripka@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5938-8917</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Соколова Анастасия Андреевна </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Anastasiya A. Sokolova </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">sokolovastasya2@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6241-2711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Напалков</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Napalkov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Напалков Дмитрий Александрович </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Dmitry A. Napalkov </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">dminap@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомин Виктор Викторович  </p><p>ул. Трубецкая, д. 8, стр. 2, Москва,119048</p></bio><bio xml:lang="en"><p>Victor V. Fomin </p><p>8-2 Trubetskaya str., Moscow, 119048 </p></bio><email xlink:type="simple">fomin_v_v_1@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>17</day><month>06</month><year>2026</year></pub-date><volume>22</volume><issue>2</issue><fpage>139</fpage><lpage>145</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tachilovich I.O., Kurnosova A.A., Kudrjavtseva A.A., Skripka A.I., Sokolova A.A., Napalkov D.A., Fomin V.V., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Тачилович И.О., Курносова А.А., Кудрявцева А.А., Скрипка А.И., Соколова А.А., Напалков Д.А., Фомин В.В.</copyright-holder><copyright-holder xml:lang="en">Tachilovich I.O., Kurnosova A.A., Kudrjavtseva A.A., Skripka A.I., Sokolova A.A., Napalkov D.A., Fomin V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3274">https://www.rpcardio.online/jour/article/view/3274</self-uri><abstract><sec><title>Aim</title><p>Aim. To develop an online calculator of individual NT-proBNP thresholds to diagnose heart failure with preserved ejection fraction (HFpEF) and to pilot it in clinical practice.</p></sec><sec><title>Material and methods</title><p>Material and methods. At the first stage, an online calculator that computes a personalised NT-proBNP threshold based on age, sex, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI), and the presence of atrial fibrillation was developed. A total of 128 patients (50% women; median age, 71 years) with HFpEF hospitalised at University Clinical Hospital No. 1, Sechenov University, between January and August 2024 were enrolled to validate the calculator. Diagnoses based on guideline-recommended NT-proBNP cutoffs were compared with diagnoses incorporating individualised thresholds from the calculator. Agreement between methods was assessed using Cohen’s kappa, and differences in diagnosis rates were evaluated with McNemar’s test.</p></sec><sec><title>Results</title><p>Results. When comparing diagnoses based on standard NT-proBNP thresholds with those using individualised values, the diagnosis changed in 38 cases (29.7%): HFpEF was established in 30 patients and excluded in 8. Cohen’s kappa was 0.35. The difference between approaches was statistically significant (p=0.0005). The greatest diagnostic discrepancies were observed in patients younger than 60 years and in those with BMI 30-34 kg/m² and ≥40 kg/m²; statistically significant differences in diagnosis frequency were found only for patients with BMI 30-34 kg/m² (k=0.38, p &lt;0.001). The minimum and maximum calculated NT-proBNP thresholds were 45 pg/mL and 506 pg/mL, respectively, delineating a “gray zone” in which the calculator may be particularly useful for refining diagnosis.</p></sec><sec><title>Conclusion</title><p>Conclusion. NT-proBNP remains a key biomarker in HFpEF diagnosis; however, patient sex, age, and comorbidities affect its circulating levels. We therefore propose using our online calculator to derive individualized NT-proBNP thresholds for HFpEF diagnosis to reduce diagnostic errors, initiate treatment in a timely manner, and avoid unnecessary medication.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Разработать онлайн-калькулятор индивидуальных пороговых значений N-концевого промозгового натрийуретического пептида (NT-proBNP) для диагностики хронической сердечной недостаточности с сохраненной фракцией выброса (ХСНсФВ) и дальнейшего его использования в клинической практике.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. На первом этапе разработан онлайн-калькулятор, вычисляющий индивидуальный пороговый уровень NT-proBNP, в котором используются возраст, пол, индекс массы тела (ИМТ), скорость клубочковой фильтрации (СКФ по формуле CKD-EPI) и наличие фибрилляции предсердий. 128 пациентов (50% женщин, медиана возраста 71 год) с ХСНсФВ, госпитализированных в Университетскую клиническую больницу №1 Сеченовского Университета в период с января по август 2024 г., были включены в исследование для проверки онлайн-калькулятора пороговых значений NT-proBNP. Проводилось сравнение диагнозов, которые были установлены по клиническим рекомендациям, где пороговые значения NT-proBNP равны 125 пг/мл при синусовом ритме и 365 пг/мл при фибрилляции предсердий, и диагнозов, поставленных по клиническим рекомендациям, но с учетом индивидуальных значений, рассчитанных с использованием калькулятора. Был рассчитан коэффициент каппа Коэна, который показывает степень согласия двух методов. Статистическую значимость различий в частоте постановки диагноза оценили с помощью критерия МакНемара.</p></sec><sec><title>Результаты</title><p>Результаты. При сравнении диагнозов, установленных с использованием стандартных пороговых значений NT-proBNP и новых индивидуальных значений, в 38 случаях (29,7%) диагноз изменился: у 30 пациентов диагноз ХСНсФВ был установлен, а у 8 пациентов он был исключен. Коэффициент каппа Коэна составил 0,35. Разница между подходами оказалась статистически значимой (p &lt;0,001). Наибольшее расхождение в диагнозах наблюдалось у пациентов моложе 60 лет и у пациентов с ИМТ 30-34 кг/м² и ≥40 кг/м². При этом статистически значимые различия в частоте диагностики были выявлены только у пациентов с ИМТ 30-34 кг/м² (k=0,38, p &lt;0,001). Минимальным рассчитанным пороговым значением NT-proBNP являлось 45 пг/мл, максимальным — 506 пг/мл, диапазон значений между ними можно выделить как «серую зону».</p></sec><sec><title>Заключение</title><p>Заключение. Разработанный онлайн-калькулятор с использованием дополнительных параметров (пол, возраст, ИМТ, СКФ, наличие ФП) позволяет рассчитать индивидуальные пороговые значения NT-proBNP, что может способствовать персонифицированному подходу к ведению пациентов с ХСНсФВ.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность с сохранной фракцией выброса</kwd><kwd>NT-proBNP</kwd><kwd>онлайн-калькулятор</kwd><kwd>индекс массы тела</kwd><kwd>скорость клубочковой фильтрации</kwd><kwd>фибрилляция предсердий</kwd><kwd>персонализированная медицина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure with preserved ejection fraction</kwd><kwd>NT-proBNP</kwd><kwd>online calculator</kwd><kwd>body mass index</kwd><kwd>estimated glomerular filtration rate</kwd><kwd>atrial fibrillation</kwd><kwd>personalised medicine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. DOI: 10.1093/eurheartj/ehz641. Еrratum in: Eur Heart J. 2021;42(13):1274. DOI: 10.1093/eurheartj/ehaa1016.</mixed-citation><mixed-citation xml:lang="en">Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. DOI: 10.1093/eurheartj/ehz641. Еrratum in: Eur Heart J. 2021;42(13):1274. DOI: 10.1093/eurheartj/ehaa1016.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. DOI: 10.1161/CIRCULATIONAHA.118.034646.</mixed-citation><mixed-citation xml:lang="en">Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. DOI: 10.1161/CIRCULATIONAHA.118.034646.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging. 2018;11(1):1-11. DOI: 10.1016/j.jcmg.2017.08.007.</mixed-citation><mixed-citation xml:lang="en">Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging. 2018;11(1):1-11. DOI: 10.1016/j.jcmg.2017.08.007.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9. DOI: 10.1056/NEJMoa052256.</mixed-citation><mixed-citation xml:lang="en">Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9. DOI: 10.1056/NEJMoa052256.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller C, McDonald K, de Boer RA, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. DOI: 10.1002/ejhf.1494.</mixed-citation><mixed-citation xml:lang="en">Mueller C, McDonald K, de Boer RA, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. DOI: 10.1002/ejhf.1494.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(6):870-6. DOI: 10.1016/j.amjcard.2012.05.014.</mixed-citation><mixed-citation xml:lang="en">Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(6):870-6. DOI: 10.1016/j.amjcard.2012.05.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. Eur Heart J. 2022;43(20):1952-4. DOI: 10.1093/eurheartj/ehac121.</mixed-citation><mixed-citation xml:lang="en">Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. Eur Heart J. 2022;43(20):1952-4. DOI: 10.1093/eurheartj/ehac121.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bayes‐Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP : A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891-8. DOI: 10.1002/ejhf.3036.</mixed-citation><mixed-citation xml:lang="en">Bayes‐Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP : A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891-8. DOI: 10.1002/ejhf.3036.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. DOI: 10.15829/1560-4071-2024-6162.</mixed-citation><mixed-citation xml:lang="en">Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2024;29(11):6162 (In Russ.) DOI: 10.15829/1560-4071-2024-6162.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guo M, Luo J, Zhao J, et al. Combined Use of Circulating miR-133a and NTproBNP Improves Heart Failure Diagnostic Accuracy in Elderly Patients. Med Sci Monit. 2018;24:8840-8. DOI: 10.12659/MSM.911632.</mixed-citation><mixed-citation xml:lang="en">Guo M, Luo J, Zhao J, et al. Combined Use of Circulating miR-133a and NTproBNP Improves Heart Failure Diagnostic Accuracy in Elderly Patients. Med Sci Monit. 2018;24:8840-8. DOI: 10.12659/MSM.911632.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Murad K, Goff DC Jr, Morgan TM, et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality. JACC Heart Fail. 2015;3(7):542-50. DOI: 10.1016/j.jchf.2015.03.004.</mixed-citation><mixed-citation xml:lang="en">Murad K, Goff DC Jr, Morgan TM, et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality. JACC Heart Fail. 2015;3(7):542-50. DOI: 10.1016/j.jchf.2015.03.004.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor CJ, Taylor KS, Jones NR, et al. Age‐adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: Diagnostic accuracy study. ESC Heart Fail. 2025;12(5):3552-68. DOI: 10.1002/ehf2.15383.</mixed-citation><mixed-citation xml:lang="en">Taylor CJ, Taylor KS, Jones NR, et al. Age‐adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: Diagnostic accuracy study. ESC Heart Fail. 2025;12(5):3552-68. DOI: 10.1002/ehf2.15383.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
